mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients?

  1. Veerle P. W. M. Wijtvliet
  2. Kevin K. Ariën
  3. Steven Abrams
  4. Marie M. Couttenye
  5. Fabienne Mestrez
  6. Joachim Mariën
  7. Benedicte Y. De Winter
  8. Pierre Van Damme
  9. Lissa Pipeleers
  10. Karl Martin Wissing
  11. Daniel Abramowicz
  12. Kristien J. Ledeganck
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

In this study of the humoral immune response after the SARS-CoV-2 mRNA vaccination, low seroconversion rates were noted in both kidney transplant recipients and dialysis patients after first dose administration. While in DP the seroconversion rate levelled up to 92.8% after a second dose of SARS-CoV-2 mRNA vaccination, KTR stayed behind with a seroconversion rate of 62.4%. Futhermore, vaccination with the mRNA-1273 vaccine (Moderna) resulted in both higher seroconversion rates and mean log-transformed antibody titer concentrations compared to BNT162b2 (Pfizer).

Related articles

Related articles are currently not available for this article.